Relypsa Overview

Relypsa, Inc. is a biopharmaceutical company leading the discovery and development of new non-absorbed polymeric drugs for important applications in cardiovascular and renal disease. The new company is a spin-out of Ilypsa, Inc., a wholly-owned subsidiary of Amgen, Inc. [Nasdaq: AMGN] (acquired by Amgen in July 2007 for $ 420 M). Relypsa commences operations with rights to a proprietary drug...More»

Relypsa, Inc. is a biopharmaceutical company leading the discovery and development of new non-absorbed polymeric drugs for important applications in cardiovascular and renal disease. The new company is a spin-out of Ilypsa, Inc., a wholly-owned subsidiary of Amgen, Inc. [Nasdaq: AMGN] (acquired by Amgen in July 2007 for $ 420 M). Relypsa commences operations with rights to a proprietary drug discovery platform and a pipeline of product candidates including a potassium binder drug candidate for the treatment of hyperkalemia, known as RELY105, as well as a novel sodium binder, RELY102, for the potential treatment of congestive heart failure. Relypsa is dedicated to discover additional product candidates through use of its proprietary polymer platform.«Less